You are browsing articles on the topic of General Archives - CardioExchange

Avatar of Larry Husten, PHD

Study Suggests Link Between Viagra and Melanoma (8 Apr 2014)

News

In recent years, researchers have uncovered a potentially important pathway whereby PDE5A inhibitors (which include sildenafil — Viagra — and other drugs used to treat erectile dysfunction and pulmonary hypertension) could potentially increase the risk for developing melanoma. Now a study provides early evidence showing an association between sildenafil and melanoma, though, like all observational…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

Avatar of Ahmad

Some Thoughts on E-Communication and the Future of Medicine (8 Apr 2014)

Voices

Ahmad M Slim, M.D.

Dr. Ahmad Slim discusses the rise of digital communication between physicians and patients.

Avatar of Richard Lehman, BM, BCh, MRCGP

Selections from Richard Lehman’s Literature Review: April 7th (7 Apr 2014)

Voices

Richard Lehman, BM, BCh, MRCGP

This week’s topics include SYMPLICITY HTN-3, CoreValve, MADIT-CRT, and more.

Avatar of Larry Husten, PHD

Dabigatran Approved for Treatment of DVT and PE (7 Apr 2014)

News

Boehringer Ingelheim announced on Monday that the FDA has approved dabigatran (Pradaxa) for the treatment of venous thromboembolism (VTE), which includes both deep venous thrombosis (DVT) and pulmonary embolism (PE), and to reduce the risk of recurrent DVT and PE in patients who have been previously treated. All three of the new oral anticoagulants — dabigatran, rivaroxaban…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

Avatar of Larry Husten, PHD

Cardiovascular Disease Declines in Rich Countries but Grows Elsewhere (3 Apr 2014)

News

A new Global Cardiovascular Disease (CVD) Atlas portrays a divided world where rich countries are gradually freeing themselves from the yoke of CVD but where many poor and middle-income countries are still struggling. Ischemic heart disease and stroke were the two biggest contributors to the global burden of disease in 2010, accounting for 5.2% and…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

Avatar of Saurav

Master of All Trades (31 Mar 2014)

Fellowship Training

Saurav Chatterjee, MD

Saurav Chatterjee reflects on the growing demands of fellows embarking on careers in private practice.

Avatar of Larry Husten, PHD

Aspirin and Clonidine Fail to Help Surgery Patients (31 Mar 2014)

News

Myocardial infarction (MI) is among the most common and serious side effects of noncardiac surgery. An effective regimen to minimize this risk has been the subject of considerable debate in recent years. The controversy was recently exacerbated because the recommendation to use beta-blockers in this setting was based on research which has now been discredited. Substantial…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

Avatar of Larry Husten, PHD

High-Sensitivity Troponin Test Could Identify Low-Risk Chest Pain Patients in the ED (30 Mar 2014)

News

Approximately 15-20 million people in Europe and the United States go to the emergency department every year with chest pain. Many can be discharged early if they are not having an acute coronary syndrome. A large, new, single-center observational study, presented at the American College of Cardiology meeting in Washington, DC and published simultaneously in the Journal…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

Avatar of Kumar

Taking Patient-Centeredness to the Next Level at ACC.14 (30 Mar 2014)

Fellowship Training

Kumar Dharmarajan, MD MBA

A fellow discusses an interesting lecture approach at ACC.14.

Avatar of Saurav

Are Digital Conferences the Way of the Future? (30 Mar 2014)

Fellowship Training

Saurav Chatterjee, MD

A fellow reflects on how technology may impact meetings in the years to come.